Trial Profile
Organization of Teratology Information Specialists (OTIS) Vedolizumab Pregnancy Exposure Registry
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2023
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Takeda
- 09 Mar 2023 Status changed from active, no longer recruiting to completed.
- 26 Oct 2022 According to Results presented at American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022, Vedolizumab Pregnancy Exposure Registry is ongoing with formal statistical analysis planned once the study is completed in 2023.
- 26 Oct 2022 Results of preliminary descriptive outcomes presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022